In a real-world study, the prevalence of immune checkpoint inhibitor–associated thyroid dysfunction was greater than 50%, but cases were mild and were even linked to better survival.
Claire F. Verschraegen, MD, discusses adverse effects that are commonly associated with the use of single-agent nivolumab vs the combination of ipilimumab plus nivolumab in melanoma.